2023 to 2024 COVID-19 Vaccine Provided Additional Effectiveness

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 2, 2025.

via HealthDay

WEDNESDAY, July 2, 2025 -- The 2023 to 2024 COVID-19 vaccine provided additional effectiveness against medically attended COVID-19, according to a study published online June 24 in JAMA Network Open.

Ruth Link-Gelles, Ph.D., M.P.H., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues conducted a case-control study to examine the vaccine effectiveness (VE) of 2023 to 2024 (monovalent XBB.1.5) COVID-19 vaccines against COVID-19-associated emergency department (ED) and urgent care (UC) encounters, hospitalizations, and critical illness among adults during periods of Omicron XBB and JN.1 predominance.

The researchers found that 37,096 (11 percent) of 345,639 eligible ED and UC encounters in immunocompetent adults with COVID-19-like illness and available test results had a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) result. During seven to 299 days after vaccination, VE against COVID-19-associated ED and UC encounters was 24 percent. Nine percent of 111,931 eligible hospitalizations in immunocompetent adults with COVID-19-like illness and available test results had a positive SARS-CoV-2 test result. VE was 29 and 48 percent against COVID-19-associated hospitalization and critical illness, respectively, during seven to 299 days after vaccination. VE was highest at seven to 59 days after vaccination (VE: 49, 51, and 68 percent against ED and UC encounters, hospitalizations, and critical illness, respectively) and then waned (VE at 180 to 299 days after vaccination, −7, −4, and 16 percent, respectively).

"The 2023-2024 COVID-19 vaccines were associated with additional protection against COVID-19-associated ED and UC encounters, hospitalization, and critical illness beyond existing protection provided by prior vaccination or SARS-CoV-2 infection," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-03 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords